Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
NL-OMON47717Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nilotinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Novartis. Primary endpoints: Major cytogenetic response rate by 6 months, Complete hematologic response rate by 3 months and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON47717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47717.